Berlin (Germany), April 30, 2024 - Jens Ravens, Executive Board member of Epigenomics AG (Frankfurt General Standard: ECX, the “Company”), leaves the Executive Board of the Company with effect as of ...
Acquirer is U.S. full-service diagnostics and CRO services company New Day Diagnostics LLC Purchase price of up to USD 12.05 million plus license and earn-out payments Berlin (Germany), July 24, 2023 ...
KNOXVILLE, Tenn.--(BUSINESS WIRE)--New Day Diagnostics LLC is pleased to announce that it has entered into an asset purchase agreement with Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) ...
Berlin, Germany, October 10, 2023 – Epigenomics AG (Frankfurt General Standard: ECX1; the“Company”) closed today the agreement entered into on July 24, 2023 with New Day Diagnostics LLC (“New Day ...
BERLIN & SEATTLE--(BUSINESS WIRE)-- Epigenomics AG (FWB:ECX), the cancer diagnosis company, today announced the appointment of Noel Doheny as the new Chief Executive Officer (CEO) of its subsidiary ...
Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024 30-Oct-2023 / 15:49 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) ...
Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024 30.04.2024 / 15:00 CET/CEST The issuer is solely responsible for the content of this announcement. Epigenomics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results